Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
International Journal of Molecular Sciences|September 23, 2022
Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden MiceFlorine Seidel, Robert Kleemann, Wim van Duyvenvoorde, et al.
Journal of Lipid Research|September 6, 2015
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9Sam J L van der Tuin, Susan Kühnast, Jimmy F P Berbée, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 28, 2024
Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-/-.Leiden miceJosé A Inia, Joline Attema, Christa de Ruiter, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 26, 2020
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivativeGeurt Stokman, Anita M van den Hoek, Ditte Denker Thorbekk, et al.
Cellular and Molecular Gastroenterology and Hepatology|December 26, 2017
Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse ModelArianne van Koppen, Lars Verschuren, Anita M van den Hoek, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 24, 2025
Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General PopulationKoen C van Son, Jelle C B C de Jong, Serdar Özsezen, et al.
Pageof 9